Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incannex Healthcare Inc. - Common Stock (NQ:IXHL)

0.3499 -0.0307 (-8.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Incannex full steam ahead towards sleep apnoea trial
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive after the company received clearance from the US Food and Drug Administration (FDA) to begin... 
Via TheNewswire.com
Topics Cannabis
Incannex full steam ahead towards sleep apnoea trial
--News Direct-- 
Via News Direct
Topics Cannabis
FDA Approves Clinical Trial Of Incannex's Dronabinol-Based Drug For Obstructive Sleep Apnea
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the US Food and Drug Administration to conduct the company’s investigational new drug (&ls 
Via Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
Incannex Healthcare: Is Life Better On Nasdaq?
Incannex Healthcare is planning to redomicile to the US in a move designed to access deeper pools of capital and increase the company’s long-term market valuation. We interview the CEO of the... 
Via Talk Markets
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
 
Via Benzinga
Topics Cannabis
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
 
Via Benzinga
Topics Cannabis
Cannabis Stock Gainers And Losers From August 16, 2023
 
Via Benzinga
Topics Cannabis
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
Cannabis Stock Gainers And Losers From August 14, 2023
 
Via Benzinga
Topics Cannabis
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
Cannabis Stock Gainers And Losers From August 11, 2023
 
Via Benzinga
Topics Cannabis
Clarion Clinics Begins Accepting Registrations For Psychedelic Treatment Interest
Clarion Clinics Group Pty Ltd, a subsidiary of Incannex Healthcare Ltd (NASDAQ: IXHL) (ASX:IHL) is now accepting direct registration of interest in treatment from potential clients via its website... 
Via Benzinga
Cannabis Stock Movers For August 10, 2023
 
Via Benzinga
Topics Cannabis
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
 
Via Benzinga
Cannabis Stock Gainers And Losers From August 4, 2023
 
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
Cannabis Stock Movers For August 3, 2023
 
Via Benzinga
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
Marijuana Stock Movers For August 2, 2023
 
Via Benzinga
Incannex thrilled with positive pre-IND meeting for arthritis treatment
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive the company has completed a constructive pre-Investigational New Drug (IND) application meeting... 
Via TheNewswire.com
Marijuana Stock Movers For August 1, 2023
 
Via Benzinga
Incannex thrilled with positive pre-IND meeting for arthritis treatment
--News Direct-- 
Via News Direct
Incannex Completes Positive Pre-IND Meeting With FDA On CBD-Based Drug For Treatment Of Rheumatoid Arthritis
Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has completed a constructive pre-Investigational New Drug Application (‘pre-IND’) meeting with the U.S. 
Via Benzinga
Cannabis Stock Gainers And Losers From July 28, 2023
 
Via Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
Cannabis Stock Gainers And Losers From July 26, 2023
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.